Garheng Kong

Garheng Kong, M.D., Ph.D. has served as a member of the board of directors since April 2020. Dr. Kong has been a founder and managing director at HealthQuest Capital Management Company, LLC, a growth equity firm focused on improving people’s lives through improving healthcare on a significant scale, since 2012. A physician, scientist, and engineer by training, Dr. Kong has over two decades of experience investing in innovative healthcare companies with a long list of successes, including over 25 initial public offering or merger and acquisition exits for emerging companies.

Dr. Kong currently serves as a member of the board of directors of biopharmaceutical companies Alimera Sciences (NASDAQ: ALIM), since 2012 and Strongbridge Biopharma (NASDAQ: SBBP), since 2015, as well as medical testing and diagnostics companies Laboratory Corporation of America Holdings (NYSE: LH). He has previously served on the board of directors of more than 30 public and private companies and as chairperson or lead director of the board of directors for nine companies. Some of his notable past successes include initial public offerings by Alimera Sciences, Inc., Applied Genetic Technology Corp., Avedro, Inc., Castle Biosciences, Inc., Cempra, Inc., Proteon Therapeutics, Inc., Pulmonx, Inc., Histogenics Corp., TransEnterix, Inc. and Venus Concept Inc.

Dr. Kong received a B.S. in Chemical Engineering and a B.S. in Biological Sciences from Stanford University. He received an M.D., an M.B.A. and a Ph.D. in Biomedical Engineering from Duke University.